Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 4—April 2021
Synopsis

Reemergence of Human Monkeypox and Declining Population Immunity in the Context of Urbanization, Nigeria, 2017–2020

Phi-Yen NguyenComments to Author , Whenayon Simeon Ajisegiri, Valentina Costantino, Abrar A. Chughtai, and C. Raina MacIntyre
Author affiliations: The Kirby Institute, Kensington, New South Wales, Australia (P.Y. Nguyen, V. Costantino, C.R. MacIntyre); The George Institute for Global Health, Sydney, New South Wales, Australia (W.S. Ajisegiri); University of New South Wales School of Population Health, Kensington (A.A. Chughtai)

Main Article

Table 2

Case definitions for monkeypox in Nigeria

Term Definition
Suspected case
 Acute illness with fever >38.3°C, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed 1–3 days later by a progressively developing rash often beginning on the face (most dense) then spreading elsewhere on the body, including soles of feet and palms of hand.
Probable case
 Meets the clinical case definition; not laboratory confirmed, but has an epidemiological link to a confirmed case
Confirmed case Clinically compatible case that is laboratory confirmed by positive IgM, PCR, or virus isolation

*From (45).

Main Article

References
  1. Nigeria Centre for Disease Control and Prevention. Monkeypox monthly situational report, December 2019 [cited 2020 Oct 1]. https://ncdc.gov.ng/themes/common/files/sitreps/5a1a9820f21136842ba43f186b8d09e7.pdf
  2. Yinka-Ogunleye  A, Aruna  O, Dalhat  M, Ogoina  D, McCollum  A, Disu  Y, et al.; CDC Monkeypox Outbreak Team. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19:872–9. DOIPubMedGoogle Scholar
  3. Sadeuh-Mba  SA, Yonga  MG, Els  M, Batejat  C, Eyangoh  S, Caro  V, et al. Monkeypox virus phylogenetic similarities between a human case detected in Cameroon in 2018 and the 2017-2018 outbreak in Nigeria. Infect Genet Evol. 2019;69:8–11. DOIPubMedGoogle Scholar
  4. Beer  EM, Rao  VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019;13:e0007791. DOIPubMedGoogle Scholar
  5. Damon  IK. Status of human monkeypox: clinical disease, epidemiology and research. Vaccine. 2011;29(Suppl 4):D54–9. DOIPubMedGoogle Scholar
  6. Heymann  DL, Szczeniowski  M, Esteves  K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 1998;54:693–702. DOIPubMedGoogle Scholar
  7. Simpson  K, Heymann  D, Brown  CS, Edmunds  WJ, Elsgaard  J, Fine  P, et al. Human monkeypox - After 40 years, an unintended consequence of smallpox eradication. Vaccine. 2020;38:5077–81. DOIPubMedGoogle Scholar
  8. Plowright  RK, Parrish  CR, McCallum  H, Hudson  PJ, Ko  AI, Graham  AL, et al. Pathways to zoonotic spillover. Nat Rev Microbiol. 2017;15:502–10. DOIPubMedGoogle Scholar
  9. World Bank. Population, total—Nigeria [cited 2020 Sep 24]. https://data.worldbank.org/indicator/SP.POP.TOTL?locations=NG
  10. World Bank. Death rate, crude (per 1,000 people)—Nigeria [cited 2020 Sep 20]. https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=NG
  11. Nigeria National Bureau of Statistics. Annual abstract of statistics. 2010 [cited 2020 Oct 1]. http://ghdx.healthdata.org/record/nigeria-annual-abstract-statistics-2010
  12. Fine  PEM, Jezek  Z, Grab  B, Dixon  H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988;17:643–50. DOIPubMedGoogle Scholar
  13. Nishiura  H, Eichner  M. Estimation of the duration of vaccine-induced residual protection against severe and fatal smallpox based on secondary vaccination failure. Infection. 2006;34:241–6. DOIPubMedGoogle Scholar
  14. Henderson  RH, Davis  H, Eddins  DL, Foege  WH. Assessment of vaccination coverage, vaccination scar rates, and smallpox scarring in five areas of West Africa. Bull World Health Organ. 1973;48:183–94.PubMedGoogle Scholar
  15. Nigeria Data Portal. Nigeria census: distribution of households, 2015 [cited 2020 Sep 24]. https://nigeria.opendataforafrica.org/xspplpb/nigeria-census
  16. Humanitarian Data Exchange. Nigeria—roads. Updated 2018 Aug 15 [cited 2020 Oct 1]. https://data.humdata.org/dataset/nigeria-roads
  17. Osadebe  L, Hughes  CM, Shongo Lushima  R, Kabamba  J, Nguete  B, Malekani  J, et al. Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo. PLoS Negl Trop Dis. 2017;11:e0005857. DOIPubMedGoogle Scholar
  18. Kunasekaran  MP. Report of monkeypox cases in 2018 in the United Kingdom. Global Biosecurity. 2019;1:140–9. DOIGoogle Scholar
  19. Mauldin  MR, McCollum  AM, Nakazawa  YJ, Mandra  A, Whitehouse  ER, Davidson  W, et al. Exportation of Monkeypox virus from the African continent. J Infect Dis. 2020;jiaa559; Epub ahead of print. DOIPubMedGoogle Scholar
  20. Rimoin  AW, Mulembakani  PM, Johnston  SC, Lloyd Smith  JO, Kisalu  NK, Kinkela  TL, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A. 2010;107:16262–7. DOIPubMedGoogle Scholar
  21. Hammarlund  E, Lewis  MW, Hansen  SG, Strelow  LI, Nelson  JA, Sexton  GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003;9:1131–7. DOIPubMedGoogle Scholar
  22. Taub  DD, Ershler  WB, Janowski  M, Artz  A, Key  ML, McKelvey  J, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med. 2008;121:1058–64. DOIPubMedGoogle Scholar
  23. Gilchuk  I, Gilchuk  P, Sapparapu  G, Lampley  R, Singh  V, Kose  N, et al. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell. 2016;167:684–694.e9. DOIPubMedGoogle Scholar
  24. Karem  KL, Reynolds  M, Hughes  C, Braden  Z, Nigam  P, Crotty  S, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol. 2007;14:1318–27. DOIPubMedGoogle Scholar
  25. Kennedy  RB, Ovsyannikova  IG, Jacobson  RM, Poland  GA. The immunology of smallpox vaccines. Curr Opin Immunol. 2009;21:314–20. DOIPubMedGoogle Scholar
  26. Quiner  CA, Moses  C, Monroe  BP, Nakazawa  Y, Doty  JB, Hughes  CM, et al. Presumptive risk factors for monkeypox in rural communities in the Democratic Republic of the Congo. PLoS One. 2017;12:e0168664. DOIPubMedGoogle Scholar
  27. Ogoina  D, Izibewule  JH, Ogunleye  A, Ederiane  E, Anebonam  U, Neni  A, et al. The 2017 human monkeypox outbreak in Nigeria-Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PLoS One. 2019;14:e0214229. DOIPubMedGoogle Scholar
  28. Izah  LN, Majid  Z, Mohd Ariff  MF, Mohammed  HI. Determining land use change pattern in southern Nigeria: a comparative study. IOP Conf Ser Earth Environ Sci. 2018;169:012040. DOIGoogle Scholar
  29. Faust  CL, McCallum  HI, Bloomfield  LSP, Gottdenker  NL, Gillespie  TR, Torney  CJ, et al. Pathogen spillover during land conversion. Ecol Lett. 2018;21:471–83. DOIPubMedGoogle Scholar
  30. Leendertz  SAJ, Stern  D, Theophil  D, Anoh  E, Mossoun  A, Schubert  G, et al. A cross-sectional serosurvey of anti-orthopoxvirus antibodies in central and western Africa. Viruses. 2017;9:278. DOIPubMedGoogle Scholar
  31. Reynolds  MG, Carroll  DS, Olson  VA, Hughes  C, Galley  J, Likos  A, et al. A silent enzootic of an orthopoxvirus in Ghana, West Africa: evidence for multi-species involvement in the absence of widespread human disease. Am J Trop Med Hyg. 2010;82:746–54. DOIPubMedGoogle Scholar
  32. Ozioko  KU, Okoye  CI, Obiezue  RN, Agbu  RA. Knowledge, attitudes, and behavioural risk factors regarding zoonotic infections among bushmeat hunters and traders in Nsukka, southeast Nigeria. Epidemiol Health. 2018;40:e2018025. DOIPubMedGoogle Scholar
  33. U.S. Geological Survey. Earth Resources Observation and Science Center. Land use, land cover, and trends in Nigeria [cited 2020 Oct 1]. https://eros.usgs.gov/westafrica/land-cover/land-use-land-cover-and-trends-nigeria
  34. Kreuder Johnson  C, Hitchens  PL, Smiley Evans  T, Goldstein  T, Thomas  K, Clements  A, et al. Spillover and pandemic properties of zoonotic viruses with high host plasticity. Sci Rep. 2015;5:14830. DOIPubMedGoogle Scholar
  35. Mucker  EM, Chapman  J, Huzella  LM, Huggins  JW, Shamblin  J, Robinson  CG, et al. Susceptibility of marmosets (Callithrix jacchus) to monkeypox virus: a low dose prospective model for monkeypox and smallpox disease. PLoS One. 2015;10:e0131742. DOIPubMedGoogle Scholar
  36. Likos  AM, Sammons  SA, Olson  VA, Frace  AM, Li  Y, Olsen-Rasmussen  M, et al. A tale of two clades: monkeypox viruses. J Gen Virol. 2005;86:2661–72. DOIPubMedGoogle Scholar
  37. Nigeria Centre for Disease Control and Prevention. Situation report: update of monkeypox outbreak in Nigeria, 2018 Feb 25 [cited 2020 Oct 2]. https://ncdc.gov.ng/themes/common/files/sitreps/7ba9ce49faf09f5212c1dbb48b31184b.pdf
  38. Fenner  F, Henderson  DA, Arita  I, Jezek  Z, Ladnyi  ID. Smallpox and its eradication. Geneva: World Health Organization; 1988.
  39. Kennedy  JS, Frey  SE, Yan  L, Rothman  AL, Cruz  J, Newman  FK, et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis. 2004;190:1286–94. DOIPubMedGoogle Scholar
  40. Sackey  J, Liverpool-Tasie  S, Salau  S, Awoyemi  T. Rural-urban transformation in Nigeria. J African Dev. 2012;14:131–68.
  41. Farrell  K. An inquiry into the nature and causes of Nigeria’s rapid urban transition. Urban Forum. 2018;29:277–98
  42. Jezek  Z, Grab  B, Dixon  H. Stochastic model for interhuman spread of monkeypox. Am J Epidemiol. 1987;126:1082–92. DOIPubMedGoogle Scholar
  43. Public Health England. Cohort study of healthcare workers receiving Imvanex®. Clin Identifier NCT03745131. 2019. [cited 2020 Oct 1]. https://clinicaltrials.gov/ct2/show/NCT03745131
  44. Petersen  BW, Kabamba  J, McCollum  AM, Lushima  RS, Wemakoy  EO, Muyembe Tamfum  JJ, et al. Vaccinating against monkeypox in the Democratic Republic of the Congo. Antiviral Res. 2019;162:171–7. DOIPubMedGoogle Scholar
  45. Nigeria Centre for Disease Control and Prevention. Weekly epidemiological report, week 17, April 2019 [cited 2020 Oct 1]. https://ncdc.gov.ng/reports/257/2020-april-week-17

Main Article

Page created: January 27, 2021
Page updated: March 18, 2021
Page reviewed: March 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external